Joshua Goldman
Sports Medicine · Los Angeles, CANPI 1689990038
Payments from drug & device makers
Across 17 payments — averaging $403.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$6K
- Biotissue Holdings Inc.$356
- Bioventus LLC$184
- Pacira Pharmaceuticals Incorporated$150
- Trice Medical, Inc.$118
- Osiris Therapeutics Inc.$105
- plus $159 from 3 others
What the payments were for
- Speaking & faculty fees$5,77584%
- Food & beverage$1,08416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 3 | $5,787 |
| Biotissue Holdings Inc. | 5 | $356 |
| Bioventus LLC | 1 | $184 |
| Pacira Pharmaceuticals Incorporated | 2 | $150 |
| Trice Medical, Inc. | 1 | $118 |
| Osiris Therapeutics Inc. | 1 | $105 |
| Johnson & Johnson | 2 | $88 |
| Tenex Health Inc. | 1 | $53 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,859 in reported general payments places this provider in the 65th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 17 | $955 |
| Nitroglycerin PatchNitroglycerin | 31 | $801 |
| Celecoxib | 12 | $667 |
| Atorvastatin Calcium | 58 | $607 |
| Levothyroxine Sodium | 25 | $558 |
| Ezetimibe | 18 | $455 |
| Tamsulosin Hcl | 20 | $222 |
| Metformin Hcl | 15 | $191 |
| Fluticasone Propionate | 15 | $173 |
| Metoprolol Succinate | 19 | $166 |
| Lisinopril | 22 | $162 |
| Amlodipine Besylate | 18 | $123 |
| Finasteride | 11 | $33 |
| Zolpidem Tartrate | 11 | $21 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Los Angeles
- Neal ElattracheLos Angeles$51M
- Carleton VangsnessLos Angeles$872K
- Kristofer JonesLos Angeles$605K
- Michael BanffyLos Angeles$578K
- Seth GamradtLos Angeles$567K
- Reza OmidLos Angeles$400K
- Orr LimpisvastiLos Angeles$335K
- George HatchLos Angeles$255K
- David McAllisterLos Angeles$186K
- Stephen LiuLos Angeles$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.